Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
Recruiting · Phase 1, Phase 2 · NCT06105554
Conditions: Multiple Myeloma
At a glance
- Research payments reported, 2025
- $70,764
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 36
About the trial
- Sponsor
- M.D. Anderson Cancer Center (with Sanofi US Services, Inc)
- Tested
- Belumosudil mesylate (drug)
- Dates
- Started 2024-01-30; completion 2029-08-31
- Results posted
- Not yet
Phase 1 is to find the recommended dose of belumosudil mesylate that can be given to patients with relapsed/refractory MM. Phase 2 is to learn if the dose of belumosudil mesylate found in Phase 1 can help to control the disease.
From ClinicalTrials.gov, last updated 2026-08-10. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Menarini Silicon Biosystems, Inc. reported $70,764 in research payments for this study in 2025 (4 payments).
Products named: Cellsearch
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $70,764
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.